<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725738</url>
  </required_header>
  <id_info>
    <org_study_id>08-583</org_study_id>
    <nct_id>NCT00725738</nct_id>
  </id_info>
  <brief_title>Intracoronary Autologous Stem Cell Transplantation in ST Elevation Myocardial Infarction: TRACIA STUDY.</brief_title>
  <acronym>TRACIA</acronym>
  <official_title>Intracoronary Autologous Stem Cell Transplantation in ST Elevation Myocardial Infarction: TRACIA Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart Institute, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center of Blood Transfusion Mexico.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Heart Institute, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the ejection fraction (EF) increase at 6 months
      follow up and major adverse cardiovascular events (MACE) after intracoronary autologous stem
      cell transplantation in ST elevation myocardial infarction patients versus a control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental trials with bone marrow cell have suggested that adult stem cell can contribute
      to regeneration of infarcted myocardial muscle and increase the neovascularization of the
      ischemic tissue.

      Post-myocardial infarction heart failure secondary to ventricular remodelation it's an
      increasing problem. A novel therapeutic approach for decrease this consequence is to induce
      the angiogeneses and regeneration of myocardial cells.

      Many trials have shown benefits through the intracoronary injection of stem cell, however the
      clinical benefit is still controversial. The present trial is a randomized single blinded
      controlled trial designed to evaluate the improvement on EF and survival in post ST elevation
      myocardial infarction patients undergoing to intracoronary autologous stem cell
      transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the mean LVEF increase by magnetic resonance imaging (MRI) at 6 months of follow up between the stem cell group and the control group.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the left ventricular end diastolic volume (LVEDV) and left ventricular end systolic volume (LVESV)with image magnetic resonance(IMR) at 6 months follow up between stem cell and control group.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the oxygen consumption during treadmill stress test (MVO2) by expired gases analysis and the incidence of MACE at 6 months follow up between stem cell and control group.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stem Cell Transplantation Group: Between the fifth and seventh day post-primary angioplasty (PTCA) we extract the stem cell from iliac crest and during the same day the patient undergoes to a new cardiac catheterization in which we perform the intracoronary injection (about 1-2 million of CD34 cells) through the infarct related artery by a PTCA &quot;over-the-wire&quot; catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Stem Cell Transplantation</intervention_name>
    <description>1-2 million of CD34 cells injected through the infarct related artery by PTCA &quot;over-the-wire&quot; catheter during multiple sequences of balloon artery occlusion with a mean duration of 30 minutes.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Stem Cell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both gender patients between 20 and 75 years old with an acute myocardial infarction
             (less 24 hrs of symptoms) undergoing to primary angioplasty.

          -  LVEF &lt; o = 45% by MRI, radioisotopic ventriculography or echocardiogram.

          -  Informed written consent.

        Exclusion Criteria:

          -  Cardiogenic Shock.

          -  Post-myocardial infarction mechanical complication

          -  Malignant ventricular arrythmias

          -  History of malignant disease during the last five years.

          -  Pregnancy

          -  Renal chronic disease with a creatinine level &gt; 2.6 mg/dl.

          -  Any kind of stroke during the last year.

          -  Any chronic disease that can affect the patient survival during the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco A Peña-Duque, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Cardiology &quot;Ignacio Chávez&quot; Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco A Peña-Duque, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Cardiology &quot;Ignacio Chávez&quot; Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco A Peña-Duque, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Cardiology &quot;Ignacio Chávez&quot; Mexico</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marco A Peña-Duque, MD</last_name>
    <phone>55732911</phone>
    <phone_ext>1235-1236</phone_ext>
    <email>penmar@cardiologia.org.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luis J Uribe-González, MD, MSc</last_name>
    <phone>55732911</phone>
    <phone_ext>1235-1236</phone_ext>
    <email>ljhonathanug@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institute of Cardiology &quot;Ignacio Chávez&quot; Mexico</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco A Peña-Duque, MD</last_name>
      <phone>55732911</phone>
      <phone_ext>1235-136</phone_ext>
      <email>pernmar@cardiologia.org.mx</email>
    </contact>
    <contact_backup>
      <last_name>Luis J Uribe-González, MD, MSc</last_name>
      <phone>55732911</phone>
      <phone_ext>1235-1236</phone_ext>
      <email>ljhonathanug@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Fause Attie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rafael A Marin-López, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco A Martínez-Ríos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Calderón-Garcidueñas, MSc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis J Uribe-González, Md, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana M Mejia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felipe Masso, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Martínez-Sánchez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Héctor González-Pacheco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Bialostozky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erick Alexanderson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aloha Meave, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ilarraza Hermes, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramón Villavicencio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrique Gómez, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorge Gaspar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eulo Lupi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergio Férez-Santander, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Figueroa, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Lange RA, Hillis LD. Reperfusion therapy in acute myocardial infarction. N Engl J Med. 2002 Mar 28;346(13):954-5.</citation>
    <PMID>11919303</PMID>
  </reference>
  <reference>
    <citation>Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003 Jan 4;361(9351):13-20. Review.</citation>
    <PMID>12517460</PMID>
  </reference>
  <reference>
    <citation>Giugliano RP, Braunwald E; TIMI Study Group. Selecting the best reperfusion strategy in ST-elevation myocardial infarction: it's all a matter of time. Circulation. 2003 Dec 9;108(23):2828-30.</citation>
    <PMID>14662688</PMID>
  </reference>
  <reference>
    <citation>Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Apr 3;348(14):1309-21. Epub 2003 Mar 31. Erratum in: N Engl J Med. 2003 May 29;348(22):2271.</citation>
    <PMID>12668699</PMID>
  </reference>
  <reference>
    <citation>Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003 Nov 13;349(20):1893-906. Epub 2003 Nov 10. Erratum in: N Engl J Med. 2004 Jan 8;350(2):203.</citation>
    <PMID>14610160</PMID>
  </reference>
  <reference>
    <citation>Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature. 2001 Apr 5;410(6829):701-5.</citation>
    <PMID>11287958</PMID>
  </reference>
  <reference>
    <citation>Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM, Itescu S. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001 Apr;7(4):430-6.</citation>
    <PMID>11283669</PMID>
  </reference>
  <reference>
    <citation>Strauer BE, Brehm M, Zeus T, Köstering M, Hernandez A, Sorg RV, Kögler G, Wernet P. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002 Oct 8;106(15):1913-8.</citation>
    <PMID>12370212</PMID>
  </reference>
  <reference>
    <citation>Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L, Hertenstein B, Ganser A, Drexler H. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004 Jul 10-16;364(9429):141-8.</citation>
    <PMID>15246726</PMID>
  </reference>
  <reference>
    <citation>Fernández-Avilés F, San Román JA, García-Frade J, Fernández ME, Peñarrubia MJ, de la Fuente L, Gómez-Bueno M, Cantalapiedra A, Fernández J, Gutierrez O, Sánchez PL, Hernández C, Sanz R, García-Sancho J, Sánchez A. Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. Circ Res. 2004 Oct 1;95(7):742-8. Epub 2004 Sep 9.</citation>
    <PMID>15358665</PMID>
  </reference>
  <reference>
    <citation>Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM; REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006 Sep 21;355(12):1210-21.</citation>
    <PMID>16990384</PMID>
  </reference>
  <reference>
    <citation>Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grøgaard HK, Bjørnerheim R, Brekke M, Müller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006 Sep 21;355(12):1199-209.</citation>
    <PMID>16990383</PMID>
  </reference>
  <reference>
    <citation>Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, Zuba-Surma EK, Al-Mallah M, Dawn B. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007 May 28;167(10):989-97. Review.</citation>
    <PMID>17533201</PMID>
  </reference>
  <reference>
    <citation>Assmus B, Honold J, Schächinger V, Britten MB, Fischer-Rasokat U, Lehmann R, Teupe C, Pistorius K, Martin H, Abolmaali ND, Tonn T, Dimmeler S, Zeiher AM. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med. 2006 Sep 21;355(12):1222-32.</citation>
    <PMID>16990385</PMID>
  </reference>
  <reference>
    <citation>Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med. 2002 Mar 14;346(11):793-801.</citation>
    <PMID>11893790</PMID>
  </reference>
  <reference>
    <citation>Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, Mark DB, McCallister BD, Mooss AN, O'Reilly MG, Winters WL, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Committee to Update the 1997 Exercise Testing Guidelines. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol. 2002 Oct 16;40(8):1531-40. Erratum in: J Am Coll Cardiol. 2006 Oct 17;48(8):1731.</citation>
    <PMID>12392846</PMID>
  </reference>
  <reference>
    <citation>Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000 Jun 27;101(25):2981-8. Review.</citation>
    <PMID>10869273</PMID>
  </reference>
  <reference>
    <citation>Froelicher V, Myers J. Exercise and the heart. Fourth edition. Ed. Saunders. Philadelphia 2000. pp 456.</citation>
  </reference>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2008</study_first_submitted>
  <study_first_submitted_qc>July 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2008</study_first_posted>
  <last_update_submitted>July 29, 2008</last_update_submitted>
  <last_update_submitted_qc>July 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>Marco Antonio Peña Duque MD Interventional Cardiologist</name_title>
    <organization>National Institute of Cardiology &quot;Ignacio Chávez&quot;</organization>
  </responsible_party>
  <keyword>Myocardial</keyword>
  <keyword>Infarction,</keyword>
  <keyword>Stem</keyword>
  <keyword>Cell</keyword>
  <keyword>Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

